Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. officer Peter Rahmer reported a sale of 50,000 shares of common stock on June 30, 2026 at a weighted average price of $19.09 per share, executed in multiple trades pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025. He also acquired 3,056 shares at $6.95 per share. After these transactions he directly holds 228,913 shares, including 9,153 shares underlying restricted stock units.
RLAY Section 144 notice reports intent related to 50,000 Performance Stock Units dated 01/29/2025 and discloses a recent sale of 753 Common shares on 04/28/2026 for $11,136.87. The filing lists Morgan Stanley Smith Barney LLC as the broker and includes a table row dated 06/30/2026.
Relay Therapeutics, Inc. reported that Chief Financial Officer Thomas Catinazzo exercised stock options and sold common shares in a series of same-day transactions. He exercised options for a total of 169,446 shares of common stock at exercise prices of $4.45, $5.22, and $5.04 per share. He then completed open-market sales totaling 187,163 shares at prices reported around $16.97–$17.01 per share, executed in multiple trades within disclosed price ranges. Following these transactions, he directly owned 177,461 shares of common stock, which include 9,807 shares underlying restricted stock units. The filing notes that at least one of the reported transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025.
Relay Therapeutics, Inc. reported that President, R&D Donald A. Bergstrom exercised options for 93,456 shares of common stock at $4.12 per share and sold 93,456 shares at a weighted average price of $16.94 per share in multiple trades ranging from $16.15 to $17.39, pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.
After these transactions, he directly holds 418,557 shares of common stock, including 15,037 shares underlying restricted stock units. The exercised option, which was fully vested and had an expiration date of April 9, 2028, now has no remaining balance.
Donald A. filed a Form 144 notice to sell common stock, listing 93,456 shares tied to an exercise of stock options with a proposed sale date of 06/22/2026. The filing also lists 17,190 shares from Restricted Stock Units dated 12/26/2021. The form records a prior sale of 1,490 shares on 04/28/2026 for $22,037.10.
Form 144 sale notice: A Form 144 filing related to RLAY lists intended dispositions of Common stock and shows multiple 10b5-1 sales executed by Thomas J. Catinazzo. The filing itemizes planned methods (including exercise of stock options) and records four recent 10b5-1 sales on 04/07/2026, 04/09/2026, 04/28/2026, and 05/14/2026 with the share counts and proceeds shown below.
Relay Therapeutics director Claire Mazumdar received a new stock option grant. The Form 4 reports an award of options covering 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date and expire on June 8, 2036. After this grant, Mazumdar holds stock options for 32,947 underlying shares directly.
Relay Therapeutics director Habib J. Dable received a new stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036. It vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual stockholder meeting. Following this grant, Dable holds options covering 32,947 underlying shares directly.
Relay Therapeutics director Linda A. Hill received a stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted as a compensation award, not an open-market purchase or sale.
The option was granted on June 9, 2026 and vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following that date. The option expires on June 8, 2036 if not exercised.
Relay Therapeutics, Inc. director Alexis Borisy reported receiving a stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036.
According to the filing, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that grant date. This is a compensation-related grant, not an open-market purchase or sale of shares.